Biotech · Private company
UniQure Biopharma B.V.
Track this companyFree. Adds UniQure Biopharma B.V. to your Dealase workspace and tells you when its record changes.
Clinical trials44 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- AAV9-hSyn1-miGRIK2Phase 2 · Mesial Temporal Lobe EpilepsyClinicalTrials.gov · fetched Nov 12, 2026
- AMT-162Phase 2 · Amyotrophic Lateral SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- AMT-191Phase 2 · Fabry DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Imitation (sham) surgeryPhase 2 · Huntington's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- intra-striatal rAAV5-miHTTPhase 2 · Huntington's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 1, 2024ClinicalTrials.gov NCT06100276 · fetched Nov 12, 2026
- AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe EpilepsyPHASE1_PHASE2 · RECRUITING · started Jun 12, 2024ClinicalTrials.gov NCT06063850 · fetched Nov 12, 2026
- Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry DiseasePHASE1_PHASE2 · RECRUITING · started Jun 5, 2024ClinicalTrials.gov NCT06270316 · fetched Nov 12, 2026
- Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's DiseasePHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 6, 2019ClinicalTrials.gov NCT04120493 · fetched Nov 12, 2026